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Cytokine Receptor Source Targets Major Function Disease Association
FLT3 Ligand Receptor 
tyrosine 
kinases
Diverse tissue DCs, other myeloid 
cells
Differentiation and 
proliferation; synergizes 
with stem cell factor
↓ = impaired hematopoietic 
stem cell repopulation and B cell 
precursors
G-CSF GCSFR dimer Macrophages, 
fibroblasts, other 
tissues
Committed 
progenitors
Differentiation 
and  activation of 
 granulocytes
↓ = neutropenia 
GM-CSF GM-CSFRα, βc T cells, 
 macrophages, 
fibroblasts, others
Macrophages, 
granulocytes, 
dendritic cells, and 
progenitors
Inflammatory; induction 
of activation; differ-
entiation, growth, and 
survival
↓ = affects alveolar function
IFNα/β/ω IFNαR1, 
IFNαR2
Macrophages, 
 fibroblasts, 
plasmacytoid DCs, 
others
NK cells, many 
others
Promotes resistance 
to viral pathogens; 
promotes increased 
expression of MHC 
class I
↓ = impaired antiviral responses
IFNγ IFNγR1, IFNγR2 Th1 cells, NK cells, 
CD8 T cells
Macrophages, NK 
cells, T cells, others
Promotes activation of 
APCs and cell-mediated 
immunity; increased 
MHC class II expression
↓ = susceptibility to intracellular 
pathogens
LIF LIFR, gp130 Macrophages,  
T cells, fibroblasts, 
uterus, others
Embryonic stem 
cells, hematopoietic 
cells, others
Cell survival ↓ = deficient  hematopoietic 
 progenitor cells; defective 
 blastocyst implantation
M-CSF Receptor 
tyrosine 
kinases
Monocytes, 
fibroblasts, others
Committed myeloid 
progenitors
Differentiation; prolifera-
tion and survival
↓ = monocyte deficiency; 
 osteopetrosis
MIF CD74 trimer, 
CD44
Macrophages, T 
cells
Macrophages Cell migration, DTH 
response
 ↓ = susceptibility to Gram-negative 
bacteria
OSM LIFR or OSM-
Rβ, gp130
Macrophages, 
fibroblasts, others
Myeloid cells, 
embryonic stem 
cells, T cells, others
Differentiation; 
induction of immune 
response (early)
Stem Cell Factor Receptor 
tyrosine 
kinases
Bone marrow Stem cells, mast 
cells
Activation and growth ↓ = impaired hematopoietic stem 
cell proliferation and melanocyte 
production
TGFβ 1,2,3 TGFβR type 
I, type II, and 
type III
T cells, DCs, 
macrophages, 
others
All leukocyte 
populations
Regulatory; inhibits 
growth and activation; 
Treg maintenance; 
synergizes with IL-6 to 
promote Th17
↓ = increased susceptibility to 
autoimmune disorders 
↑ = fibrotic diseases
TSLP Ligand TSLPR, IL7Rα Skin, lung, and gut DCs and other 
myeloid cells
Promotes Th2 develop-
ment (human); B cell 
development (mouse)
↑ = atopic diseases
SnapShot: Cytokines I-IV
Cytokines I highlights the first 16 interleukins, which were named in the order of their discovery. Many of the interleukins listed form homodi-
meric compounds and use the γc and/or βc chains in their receptors. (Cell 132, p. 324)
Cytokines II describes the remainder of the numerically named interleukins, many of which were discovered during the last decade. Due to the 
complexity of the heterodimeric ligands and receptors used by some of these factors, they present a unique challenge in the elucidation of their 
function during health and disease. (Cell 132, p. 500)
Cytokines III reviews the TNF family. Two important features of this group include the homotrimeric motif for both the ligands and the receptors 
and the capacity for bi-directional signaling. Targeting this family of inflammatory modulators has revolutionized the treatment of autoimmune 
disorders such as rheumatoid arthritis. (Cell 132, p. 900)
Cytokines IV includes many of the factors discovered prior to the current scheme for interleukin nomenclature. For historical reasons, the origi-
nal names are still in use. Note that many of these factors share receptors with other interleukins, such as IL-7Rα and gp130, which are used by 
TSLP and IL-6, respectively. (Cell 132, p. 1062)
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Abbreviations
DTH, delayed type hypersensitivity; FLT-3, fms-like tyrosine kinase-3; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; DC, dendritic cells; NK, 
natural killer cells; LIF, leukemia inhibitory factor; MIF, macrophage migration inhibitory factor; OSM, oncostatin M; TGFβ, transforming growth factor beta; Treg, regulatory T 
cells; TSLP, thymic stromal lymphopoietin.
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